TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT05174052: Dapagliflozin in Patients With Atrial Fibrillation (DAPA-AF)

Sponsor: University of Oklahoma · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 28 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$9,947,384

Rescue Site Savings

+$6,553,016

Unlock Full NCT05174052 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05174052 Rescue Dossier →